FIELD: medicine.
SUBSTANCE: group of inventions is connected to the methods of plasm HbAlc level, delay or retardation of hyperglycemia development and delay or retardation of hyperglycemia aggravation of patient with diabetes who suffers from at least one cardiovascular disease where cardiovascular diseases are chosen of the group consisting of cardiac failure, backward heart failure, acute heart failure, ischemia, recurrent ischemia, myocardial infarction, arrhythmia, acute coronary syndrome and intermittent lameness. The patient receives effective quantity of N-(2,6-dimethylfenyl)-4-[2-hydroxy-3-(2-methoxyfenoksy)-propyl]-1-piperazine acetamide (rhanolazine) or its pharmaceutically applicable salt.
EFFECT: group of inventions ensures decrease of plasm HbAlc level in treatment of cardiovascular diseases thus reducing the number of drugs necessary for the patient.
20 cl, 8 dwg, 2 tbl, 11 ex
